May 17, 2016 ReWalk Announces Collaboration with Harvard University’s Wyss Institute to Develop Lightweight and Soft Exoskeleton Systems for the Treatment of Stroke, Multiple Sclerosis and Limited Mobility Patients View Article
May 16, 2016 Foamix Names Dr. Stanley Hirsch as Chairman, and Dr. Dalia Megiddo as a Member of the Board of Foamix Pharmaceuticals View Article
May 10, 2016 Foamix Reports First Quarter 2016 Financial Results and Provides Business Update View Article
May 9, 2016 ReWalk: Commercial Health Insurance Company Becomes First to Implement Medical Policy Finding Powered Exoskeletons Medically Necessary View Article
May 9, 2016 Foamix Announces Dosing of First Patient in Phase 3 Acne Studies for Minocycline Foam FMX101 View Article
May 5, 2016 Department of Veterans Affairs Purchases 20 ReWalk Systems to Support National Multi-Center Trial Assessing Personal Exoskeleton System Use View Article
May 3, 2016 Foamix Announces Completion of Enrollment in Phase 2 Clinical Trial of Minocycline Foam (FMX103) for Treatment of Papulopustular Rosacea View Article
April 20, 2016 First-Ever Meta-Analysis of Exoskeleton Technologies Concludes Powered Exoskeleton Systems Permit Safe Ambulation in Real-Life Settings and Produce Health Benefits View Article
